EndotyPIng PreHospitAl de Novo Acute hYpoxemic Respiratory Failure

What this Trial Is About

Researchers are studying critically ill adults who arrive at the emergency department with new acute hypoxemic respiratory failure (AHRF), a severe condition affecting lung oxygen levels. The study aims to identify different biological subtypes, or endotypes, of AHRF by analyzing changes in blood proteins over 24 hours. It also seeks to find which early clinical, imaging, physiological, and biological factors relate to patient outcomes like death or ongoing severe low oxygen. Participants are adults with AHRF needing at least 5 liters per minute of oxygen to keep oxygen saturation at 90% or higher and who are newly experiencing this condition without previous long-term oxygen use. The study collects two blood samples 24 hours apart to track biomarker changes and builds models to predict risks of death or persistent severe hypoxemia. It also creates a protein panel to improve outcome prediction. The study organizes a registry and biobank of these patients for research. During the study, researchers collect clinical data, radiological images, physiological measures, and biological samples soon after emergency department presentation. They follow participants for up to 28 days or until hospital discharge or death, tracking outcomes like mortality, days free from intensive care, ventilators, or other supports, and infection occurrences. The main measure is identifying dynamic AHRF endotypes through blood protein patterns. This observational study involves no treatment but detailed monitoring and data collection to understand AHRF better.

EndotyPIng PreHospitAl de Novo Acute hYpoxemic Respiratory Failure